Connection between dermatomyositis and montelukast sodium use: A case report

doi:10.5314/wjd.v10.i2.10

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 2

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9274)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

305

WORD

HTML

3411

Figures (1-1)

490

Tables (1-2)

482

Sum=4779

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

625

Download

2088

Sum=2713

Publishing Process of This Article

Item

Count

Browse

482

Download

1311

Sum=1793

Sep 2, 2022 (publication date) through Mar 18, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Dermatology

ISSN

2218-6190

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Dermatol. Sep 2, 2022; 10(2): 10-16
Published online Sep 2, 2022. doi: 10.5314/wjd.v10.i2.10

Connection between dermatomyositis and montelukast sodium use: A case report

Mohammed H Aly, Abdulrahman A Alshehri, Abdelgaffar Mohammed, Murouj Adnan Almaghrabi, Malek M Alharbi

Mohammed H Aly, Abdelgaffar Mohammed, Department of Internal Medicine, Security Forces Hospital, Makkah 21599, Saudi Arabia

Abdulrahman A Alshehri, Department of Rheumatology, Security Forces Hospital, Makkah 21599, Saudi Arabia

Murouj Adnan Almaghrabi, Malek M Alharbi, College of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia

Author contributions: Aly MH, Alshehri AA and Mohammed A have reviewed the literature and contributed to manuscript drafting; Almaghrabi MA analyzed and interpreted the imaging findings and contributed to manuscript drafting; Alharbi MM was responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.

Informed consent statement: The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given consent for his images and other clinical information to be reported in the Journal. The patient understands that his names and initials will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Corresponding author: Murouj Adnan Almaghrabi, MBBS, Doctor, College of Medicine, Umm Al-Qura University, Al-Abdia Main Campus, 8WCQ+4RM, Makkah 24382, Saudi Arabia. murouj.a.a@gmail.com

Received: March 6, 2022
Peer-review started: March 6, 2022
First decision: April 13, 2022
Revised: April 22, 2022
Accepted: July 26, 2022
Article in press: July 26, 2022
Published online: September 2, 2022
Processing time: 178 Days and 6.6 Hours

Abstract

BACKGROUND

Montelukast or Singulair is a leukotriene receptor antagonist that reduces inflammation and relaxes the smooth muscles. It is known to be a safe and tolerable drug; nevertheless, it might be associated with several mild to severe adverse effects, one of which is dermatomyositis. Dermatomyositis is a rare acquired autoimmune myositis of unknown cause affecting adults and children. The literature has infrequently reported the association between dermatomyositis and montelukast use.

CASE SUMMARY

The current study reports a case of a 48-year-old black woman with a previous history of bronchial asthma and allergic rhinosinusitis who presented with typical signs and symptoms of dermatomyositis which were confirmed by investigations. Before developing dermatomyositis, the patient was prescribed montelukast for atopy and consumed the drug for five months. After administration of prednisolone, the patient had a significant improvement and is still being followed up.

CONCLUSION

Even though montelukast is widely used and believed to be a safe drug for managing several conditions, the present case report highlights the possibility of adverse effects of montelukast. Therefore, future studies with advanced study designs are highly recommended to investigate the association between dermatomyositis and montelukast use.

Keywords: Montelukast; Singulair; Adverse effects; Dermatomyositis; Asthma medication; Case report

Core Tip: Even though montelukast is widely used and believed to be a safe drug for managing several conditions, the present case report brings to light the possibility of adverse effects of montelukast. Especially in such a rare and serious complication of montelukast, physicians must be aware of the presentation of dermatomyositis, the diagnostic modalities, and the best treatment options for the patients, as the prompt diagnosis will prevent further complications progression of the condition.